DOCSLIB.ORG

Suppression of Pituitary Tumor Growth and Function by Ergot Alkaloids1' 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Suppression of Pituitary Tumor Growth and Function by Ergot Alkaloids1' 2 [CANCER RESEARCH 33, 849-855, April 1973] Suppression of Pituitary Tumor Growth and Function by Ergot Alkaloids1' 2 Robert M. MacLeod3 and Joyce E. Lehmeyer Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22901 SUMMARY mammary tumorigenesis. Among the drugs that are of considerable interest in control of prolactin release are the The in vivo and in vitro effects of ergot derivatives on ergot alkaloids. prolactin and growth hormone biosynthesis in the rat have Nagasawa and Meites (9) and Wuttke et al. ( 14) have shown been studied. Injection with 0.05 or 0.2 mg ergotamine that ergocornine in vivo decreases serum and pituitary tartrate had no effect on in vitro prolactin synthesis by the prolactin levels. When added in vitro, it decreases the release of pituitary gland. Ergocornine and ergocryptine, however, prolactin by the pituitary gland (3). It has also been shown inhibited both synthesis and release of prolactin. Incubation of that both ergocornine and ergocryptine inhibit the growth of glands with 4 or 40 /nM ergotamine greatly decreased prolactin 7,12-dimethylbenzanthracene-induced mammary tumors (1,9) synthesis and release but had no effect on growth hormone. and the growth of spontaneous mammary tumors as well (12). Ergocornine, 10 /¿M,and ergocryptine, 10 juM, almost Yanai and Nagasawa (16) demonstrated that ergocornine completely blocked prolactin release and decreased synthesis inhibited the appearance of spontaneous mammary tumors and release of growth hormone as well. and suppressed prolactin secretion in mice. Recently, we Daily administration of 0.05 mg ergotamine for 13 days to reported our finding that ergotamine, ergocryptine, and rats bearing the prolactin- and adrenocorticotropic hormone- ergocornine were all effective in suppressing growth of several secreting pituitary Tumor 7315a dramatically inhibited tumor pituitary tumors (7). Similarly, Quadri et al. (11) found that growth and reversed the adrenal hypertrophy caused by the injection of ergocornine or ergonovine induced regression of tumor adrenocorticotropic hormone. Ergotamine, ergo the growth of the prolactin-secreting pituitary Tumor cryptine, and ergocornine were all effective in suppressing the MtTWIS. growth of pituitary tumors and reversed the spleno- The present study is in agreement with these latter reports hepatomegalia caused by growth hormone-secreting tumors. In on the effects of ergot alkaloids on pituitary tumors. addition, the ergots decreased the high circulating prolactin Additionally, the work presented here demonstrates that the levels found in tumor-bearing animals. Ergotamine alone was primary effect of ergotamine on animals bearing pituitary able to overcome the atrophy of the pituitary glands of tumors is a direct, suppressive effect on the tumor itself, rather tumor-bearing animals and allow gland function to return than on the pituitary gland of the host. toward normal. Ergocryptine and ergocornine tended further to suppress gland function. These data demonstrate that MATERIALS AND METHODS hormone synthesis and release by the pituitary gland and pituitary tumors can be inhibited by derivatives of the ergot Animals. Mature Wistar-Furth rats (obtained from A. R. alkaloids. Schmidt Co., Inc., Madison, Wis.) were inoculated with pituitary Tumors MtTWS, MtTWIS, and SMtTWS as pre viously described (5). Pituitary Tumor 7315a was transplanted INTRODUCTION into mature female Buffalo rats (obtained from Simonsen Laboratories, Gilroy, Calif.). Mature female Sprague-Dawley For the past several years, investigations in this laboratory rats were obtained from Flow Research Animals, Dublin, Va. have been directed toward the mechanisms governing the All rats were routinely housed 4 to 5/cage at 22—23°and function of the pituitary gland and the function of pituitary allowed water and Purina laboratory chow ad libitum. tumors. More specifically, we have been interested in the Materials. Tissue Culture Medium 199 was obtained from endocrine mechanisms involved in prolactin synthesis and Microbiological Associates, Bethesda, Md. Leucine-4,5-3H, release by the pituitary gland and have been ultimately 29.8 Ci/mmole, was a product of International Chemical and concerned with the role of this hormone in supporting Nuclear Corp., Irvine, Calif. Ergotamine tartrate, ergocryptine, and ergocornine maléatewere gifts from Sandoz Pharmaceuti 1This investigation was supported by USPHS Grant CA-07535 from cals, Hanover, N. J. In some cases, the ergotamine tartrate the National Cancer Institute. injected was Gynergen (Sandoz). The drugs were all injected 'Portions of this work were presented at the Annual Meeting of the s.c. American Association for Cancer Research, 1972. Organ Culture. Incorporation of leucine-4,5-3H into prolac 'Investigation conducted while a recipient of Research Career Development Award CA-07665 from the National Cancer Institute. tin and growth hormone was studied by incubating bisected Received September 5, 1972; accepted January 8, 1973. pituitary glands in 0.5 or 1 ml of Tissue Culture Medium 199 APRIL 1973 849 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 1973 American Association for Cancer Research. Robert M. MacLeod and Joyce E. Lehmeyer containing 5 to 10 juCi of leucine-4,5-3H. Flasks were protocol supplied by the Hormone Distribution Program, incubated for 6 to 7 hr at 37°in a Dubnoff shaker and were National Institute of Arthritis and Metabolic Diseases. The gassed with 95% O2 -5% C02 . Pituitary glands were homoge prolactin provided was iodinated either with '2 51 or '3 ' I, nized in 0.5 to 1 ml of 50 mM phosphate (pH 7.2) with a glass obtained from New England Nuclear, Boston, Mass. Sheep homogenizer fitted with a Teflon pestle. Homogenates were anti-rabbit y-globulin was obtained from Dr. Ann J. Johanson frozen and thawed 3 times to lyse all granules. Duplicate of the University of Virginia Medical School. aliquots (50 //I) were then subjected to polyacrylamide gel Statistical Analysis of Experimental Data. When appro electrophoresis (4), with the sample, stacking, and separating priate, results are expressed as the mean ± S.E. The gel system of Jones et al. (2). The incubation medium proteins significance of the difference between the means was were separated on gels as well, but the 50-/J.I aliquots were determined by Student's t test. "top-loaded" according to the system described by Reisfeld et al. (13). The proteins on the gels were stained with Amido RESULTS black and band quantitated by means of a Canalco micro- densitometer with an integrator. The hormone bands on the The effects of ergot alkaloids on pituitary gland function in gels were identified by comparing their mobility with purified normal female rats are illustrated in Chart 1. The open bars in preparations of prolactin and growth hormone. Our results are the chart represent the labeled prolactin or growth hormone found in the incubation medium at the termination of the in excellent agreement with those of Jones et al. (2), who incubation. The open bars, therefore, indicate "release" of eluted these proteins from the polyacrylamide gels and established their identity by bioassay. After the identity of the newly synthesized hormone into the medium during the hormone bands was established, the bands were cut, placed in incubation period. The shaded bars represent the labeled counting vials, and dissolved in 0.5 ml 30% HjC^ at 100°. prolactin or growth hormone found in the pituitary tissue at After addition of a Triton-toluene counting solution, the vials termination of incubation. The total height of both the open were placed in a scintillation counter to determine the level of and shaded bars is the sum of the newly synthesized hormone released into the medium and that remaining within the tissue radioactivity. and is termed "total synthesis." Daily injection of 0.05 or 0.2 Prolactin Radioimmunoassay. The immunoassay of sera and incubation media was carried out using the reagents and mg ergotamine tartrate for 7 days had no effect on the release of prolactin by the pituitary gland or on total in vitro PROLACTIN synthesis of prolactin. The injection of ergocornine, however, resulted in a decrease in release of newly synthesized prolactin into the incubation medium (open bar) and a subsequent 10 accumulation of the labeled hormone within the pituitary gland (shaded bar). There was no significant effect on total rii prolactin synthesis. Ergocryptine injection almost completely * blocked prolactin release. Newly synthesized prolactin accu mulated within the tissue (shaded bar), but total synthesis was decreased compared with the control. Injection of 0.2 mg of o the drugs resulted in a slight increase in total growth hormone I synthesis. This increase in growth hormone synthesis may be an example of the reciprocal relationship between prolactin t^•I—i-i-Controi1Hh»HW1T1M n u Km U N and growth hormone, a preliminary report on which has recently appeared (8). The in vitro effects of the ergots are shown in Chart 2. a Although ergotamine had no effect on in vitro pituitary *•Tj'-I-_!>_-I-Ergotamin« hormone synthesis when injected (Chart 1), incubation of pituitary glands with a 4 ¿/Mdrug concentration resulted in a greatly decreased release of prolactin into the medium (open bar) and a subsequent accumulation of labeled prolactin within the tissue (shaded bar). Total in vitro synthesis of prolactin was also significantly decreased with respect to the Ergocty0.05 Control Ergotomin« Control Ergocor mg doily 0.2 mg daily ninitini0.2 control. At 40 /^M, the effect of ergotamine on release and mg 0.2mgdoily daily total synthesis of prolactin was even more pronounced. No effect on growth hormone production was observed. Ergocor Chart 1. Effect of administration of ergot derivatives on in vitro nine and ergocryptine, 10 juM, almost completely blocked synthesis and release of prolactin and growth hormone. Bisected female rat pituitary glands were incubated with leucine-4,5-3H for 6 to 7 hr. release of prolactin (open bar) and greatly decreased total The prolactin and growth hormone in the incubation medium and in synthesis as well.
Load more

Recommended publications
  • Ergot Alkaloid Biosynthesis in Aspergillus Fumigatus : Association with Sporulation and Clustered Genes Common Among Ergot Fungi
    Graduate Theses, Dissertations, and Problem Reports 2009 Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Coyle, Christine M., "Ergot alkaloid biosynthesis in Aspergillus fumigatus : Association with sporulation and clustered genes common among ergot fungi" (2009). Graduate Theses, Dissertations, and Problem Reports. 4453. https://researchrepository.wvu.edu/etd/4453 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Ergot alkaloid biosynthesis in Aspergillus fumigatus: Association with sporulation and clustered genes common among ergot fungi Christine M. Coyle Dissertation submitted to the Davis College of Agriculture, Forestry, and Consumer Sciences at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Genetics and Developmental Biology Daniel G. Panaccione, Ph.D., Chair Kenneth P. Blemings, Ph.D. Joseph B.
    [Show full text]
  • United States Patent
    Patented Aug. 17, 1948 2,447,214 UNITED STATES PATENT OFF ICE 2,447,214 OPTICALLY ACTIVE SALTS OF THE LY SERGIC AND SOLYSERGIC ACD DE RVATIVES AND A PROCESS FOR, THER PREPARATION AND SOLATION Arthur Stoll and Albert Hofmann, Basel, Switzer land, assignors to Sandoz Ltd., Fribourg, Swit zerland, a Swiss firm No Drawing. Application August 23, 1943, Serial No. 499,714. In Switzerland September 16, 1942 16 Claims. (CI. 260-236) 2 The preparation and the isolation of the thera The synthetically prepared derivatives of the peutically valuable and active derivatives con lysergic acid which also correspond to the above tained in ergot is a problem that has occupied cited formula possess also the same lability as chemistry and pharmacy for more than 120 years. the natural lysergic acid derivatives. Their is0 Actually it is known that the action of ergot is 5 lation and preparation encounters the same dif due to the alkaloids contained therein, which have ficulties as in the case of the lysergic acid hydra been isolated in recent years and which are zides C15H15N2CONHNH2 (made according to U. S. always present as pairs of isomers. Chrono Letters Patent 2,090,429) and in the case of the logically the following alkaloids have become alkaloids of the type of ergobasine, which can be 0 prepared by partial synthesis and in which the known up to noW: lysergic acid is combined with an amine in form Ergotinine (1875). Ergotoxine (1906) of an acid amide (see U. S. Letters Patent No. Ergotamine (1918) Ergotaminine (1918) 2,090,430).
    [Show full text]
  • Risk Assessment of Argyreia Nervosa
    Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos Risk assessment of Argyreia nervosa RIVM letter report 2019-0210 W. Chen | L. de Wit-Bos RIVM letter report 2019-0210 Colophon © RIVM 2020 Parts of this publication may be reproduced, provided acknowledgement is given to the: National Institute for Public Health and the Environment, and the title and year of publication are cited. DOI 10.21945/RIVM-2019-0210 W. Chen (author), RIVM L. de Wit-Bos (author), RIVM Contact: Lianne de Wit Department of Food Safety (VVH) [email protected] This investigation was performed by order of NVWA, within the framework of 9.4.46 Published by: National Institute for Public Health and the Environment, RIVM P.O. Box1 | 3720 BA Bilthoven The Netherlands www.rivm.nl/en Page 2 of 42 RIVM letter report 2019-0210 Synopsis Risk assessment of Argyreia nervosa In the Netherlands, seeds from the plant Hawaiian Baby Woodrose (Argyreia nervosa) are being sold as a so-called ‘legal high’ in smart shops and by internet retailers. The use of these seeds is unsafe. They can cause hallucinogenic effects, nausea, vomiting, elevated heart rate, elevated blood pressure, (severe) fatigue and lethargy. These health effects can occur even when the seeds are consumed at the recommended dose. This is the conclusion of a risk assessment performed by RIVM. Hawaiian Baby Woodrose seeds are sold as raw seeds or in capsules. The raw seeds can be eaten as such, or after being crushed and dissolved in liquid (generally hot water).
    [Show full text]
  • Genetics, Genomics and Evolution of Ergot Alkaloid Diversity Carolyn A
    University of Kentucky UKnowledge Plant Pathology Faculty Publications Plant Pathology 4-2015 Genetics, Genomics and Evolution of Ergot Alkaloid Diversity Carolyn A. Young The Samuel Roberts Noble Foundation Christopher L. Schardl University of Kentucky, [email protected] Daniel G. Panaccione West Virginia University Simona Florea University of Kentucky, [email protected] Johanna E. Takach The Samuel Roberts Noble Foundation See next page for additional authors Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/plantpath_facpub Part of the Plant Pathology Commons Repository Citation Young, Carolyn A.; Schardl, Christopher L.; Panaccione, Daniel G.; Florea, Simona; Takach, Johanna E.; Charlton, Nikki D.; Moore, Neil; Webb, Jennifer S.; and Jaromczyk, Jolanta, "Genetics, Genomics and Evolution of Ergot Alkaloid Diversity" (2015). Plant Pathology Faculty Publications. 45. https://uknowledge.uky.edu/plantpath_facpub/45 This Article is brought to you for free and open access by the Plant Pathology at UKnowledge. It has been accepted for inclusion in Plant Pathology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Authors Carolyn A. Young, Christopher L. Schardl, Daniel G. Panaccione, Simona Florea, Johanna E. Takach, Nikki D. Charlton, Neil Moore, Jennifer S. Webb, and Jolanta Jaromczyk Genetics, Genomics and Evolution of Ergot Alkaloid Diversity Notes/Citation Information Published in Toxins, v. 7, no. 4, p. 1273-1302. © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
    [Show full text]
  • Codergocrine Mesilate(BAN)
    Antidementia Drugs/Codergocrine Mesilate 363 been shown to be well tolerated and effective, but further 37. National Collaborating Centre for Mental Health/NICE. De- Choline Alfoscerate (rINN) mentia: the NICE-SCIE guideline on supporting people with de- studies are needed to establish their role. mentia and their carers in health and social care (issued Novem- Alfoscerato de colina; Choline, Alfoscérate de; Choline Alpho- 1. Cummings JL. Dementia: the failing brain. Lancet 1995; 345: ber 2006). Available at: http://www.nice.org.uk/nicemedia/pdf/ scerate; Choline Glycerophosphate; Cholini Alfosceras; L-α-Glyc- 1481–4. Correction. ibid.; 1551. CG42Dementiafinal.pdf (accessed 27/05/08) erylphosphorylcholine. Choline hydroxide, (R)-2,3-dihydroxy- 2. Fleming KC, et al. Dementia: diagnosis and evaluation. Mayo 38. Amar K, Wilcock G. Vascular dementia. BMJ 1996; 312: Clin Proc 1995; 70: 1093–1107. 227–31. propyl hydrogen phosphate, inner salt. 3. Rabins PV, et al. APA Work Group on Alzheimer’s Disease and 39. Konno S, et al. Classification, diagnosis and treatment of vascu- Холина Альфосцерат other Dementias. Steering Committee on Practice Guidelines. lar dementia. Drugs Aging 1997; 11: 361–73. C H NO P = 257.2. American Psychiatric Association practice guideline for the 8 20 6 treatment of patients with Alzheimer’s disease and other de- 40. Sachdev PS, et al. Vascular dementia: diagnosis, management CAS — 28319-77-9. mentias. Second edition. Am J Psychiatry 2007; 164 (12 suppl): and possible prevention. Med J Aust 1999; 170: 81–5. ATC — N07AX02. 5–56. Also available at: http://www.psychiatryonline.com/ 41. Farlow MR. Use of antidementia agents in vascular dementia: ATC Vet — QN07AX02.
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,673,681 Poli 45 Date of Patent: Jun
    United States Patent (19) 11 Patent Number: 4,673,681 Poli 45 Date of Patent: Jun. 16, 1987 54 PHARMACEUTICAL METHODS HAVING tine and Amitriptyline in the Treatment of Endigenous DOPAMNERGIC ACTIVETY Depression. 75 Inventor: Stefano Poli, Milan, Italy The Lancet, vol. 1, p. 735, Apr. 8, 1978. Physician's Desk Reference 1982, p. 1684-San 73) Assignee: Poli Industria Chimica S.p.A., Milan, doz-Cont, Italy Critical Analysis of the Disability in Parkinson's Dis 21) Appl. No.: 847,395 ease by: David D. Webster, MD. 22 Filed: Apr. 2, 1986 Chem. Abst. (1969)-71 4228ip. 30) Foreign Application Priority Data Primary Examiner-Stanley J. Friedman Apr. 4, 1985 IT Italy ............................... 20234 A/85 Attorney, Agent, or Firm-Michael J. Striker 51) Int. Cl“.............................................. A61K 31/44 57 ABSTRACT 52 U.S.C. .................................................... 54/288 A pharmaceutical composition containing a-dihydroer 58) Field of Search......................................... 514/288 gocryptine, or a salt thereof, is used in combination with 56) References Cited pharmaceutically acceptable carrier means or excipient PUBLICATIONS for the treatment of Parkinson's disease, depression or A Rating Scale for Depression by: Max Hamilton. cephalalgias is disclosed. A method for administering The Evaluation of Extrapyramidal Disease by: Roger the composition to a patient is also provided. C. Duvoisin. A Comparative, Multicenter Trial between Bromocrip 4 Claims, No Drawings 4,673,681 1. 2 PHARMACEUTICAL METHODS HAVING TABLE -continued DOPAMNERGIC ACTIVITY De novo BASAL WEEKS OF TREATMENT patients VALUES 2 5 1 6 The present invention concerns a new therapeutical 5.87 5.61 5.27 5.57 555 use of a-dihydroergocryptine and pharmaceutical com Legend to Table 1 positions containing the same as an active agent for the WRS; Webster Rating Scale (Webster, D.
    [Show full text]
  • Phoretic Analysis of Ergot Alkaloids. Relations Mobility in the Cle Vine
    Acta Pharm, Suecica 2, 357 (1965) Thin-layer chromatographic and thin-layer electro- phoretic analysis of ergot alkaloids.Relations between structure, RM value and electrophoretic mobility in the cle vine series STIG AGUREll DepartMent of PharmacOgnosy, Kunql, Farmaceuliska Insiitutei, StockhOLM, Sweden SUMMARY A thin-layer chromatographic and electrophoretic study of the ergot alkaloids has been made, to find rapid methods for the separation and identification of the known ergot alkaloids. The mobilities of ergot alkaloids in several useful chromatographic and electrophore- tic systems are recorded. Relations have been observed between structure and R" value in methanol-chloroform on Silica Gel G. A simple, rapid thin-layer electrophoretic technique has been de- vised for separation of ergot alkaloids, and a relation between structure and electrophoretic mobility is evident. Two-dimensional combinations of thin-layer chromatography and thin-layer electro- phoresis and chromatography are described. Numerous paper chromatographic procedures have been published for separation of the ergot alkaloids and their derivatives. Hofmann (1) and Genest & Farmilio (2) have recently listed these systems. The general advantages of thin-layer chromatography (TLC) over paper partition chromatography are well known: shorter time of equilibration and devel- opment, generally better resolution, smaller amounts of substance rc- quired, and wider choice of reagents. Several reports of TLC of ergot alkaloids have been published. In gene- ral, these investigations (2-6 and others) have dealt 'with limited groups of alkaloids, or with a specific problem involving at most a dozen of the 40 now known naturally occurring ergot alkaloids. Some paper chromate- .357 graphic systems using Iorrnamide-treated papers have also been adopted for thin-layer chromatographic use (7, 8).
    [Show full text]
  • Diversification of Ergot Alkaloids in Natural and Modified Fungi
    Toxins 2015, 7, 201-218; doi:10.3390/toxins7010201 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Diversification of Ergot Alkaloids in Natural and Modified Fungi Sarah L. Robinson and Daniel G. Panaccione * Division of Plant and Soil Sciences, West Virginia University, Morgantown, WV 26506, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-304-293-8819; Fax: +1-304-293-2960. Academic Editor: Christopher L. Schardl Received: 21 November 2014 / Accepted: 14 January 2015 / Published: 20 January 2015 Abstract: Several fungi in two different families––the Clavicipitaceae and the Trichocomaceae––produce different profiles of ergot alkaloids, many of which are important in agriculture and medicine. All ergot alkaloid producers share early steps before their pathways diverge to produce different end products. EasA, an oxidoreductase of the old yellow enzyme class, has alternate activities in different fungi resulting in branching of the pathway. Enzymes beyond the branch point differ among lineages. In the Clavicipitaceae, diversity is generated by the presence or absence and activities of lysergyl peptide synthetases, which interact to make lysergic acid amides and ergopeptines. The range of ergopeptines in a fungus may be controlled by the presence of multiple peptide synthetases as well as by the specificity of individual peptide synthetase domains. In the Trichocomaceae, diversity is generated by the presence or absence of the prenyl transferase encoded by easL (also called fgaPT1). Moreover, relaxed specificity of EasL appears to contribute to ergot alkaloid diversification. The profile of ergot alkaloids observed within a fungus also is affected by a delayed flux of intermediates through the pathway, which results in an accumulation of intermediates or early pathway byproducts to concentrations comparable to that of the pathway end product.
    [Show full text]
  • Unlted States Patent [19] [11] Patent Number: 5,069,911 Ziiger [45] Date of Patent: Dec
    Unlted States Patent [19] [11] Patent Number: 5,069,911 Ziiger [45] Date of Patent: Dec. 3, 1991 [54] PHARMACEUTICAL 4,229,451 10/ 1980 Fehr et a1. ......................... .1 514/250 QJWDIHYDROGENATED ERGOT 4,239,763 12/1980 Milavec et a1, . 514/250 ALKALOID CONTAINING COMPOSITIONS 4,251,529 2/1981 Maurer et al. .. 514/250 _ 4,259,314 3/1981 Lowey . .. 424/469 [75] Inventor: Othmar Ziiger, Allschwil, 4,315,937 2/1982 Maclay et al. 514/250 Switzerland 4,389,393 6/1983 Schor et al. 424/469 _ . 4,411,882 10/1983 Franz . .. 424/462 [73] Asslgncer Smdol Ltd-, Basel, swltzerland 4,440,772 4/1984 Ojordjevic er a1. 514/250 _ 4,479,911 10/1984 Fong . .. 424/497 [21] Appl. No.. 542,457 4,777,033 10/1988 Ikura et al 424/81 {22] Filed, Jun. 22, 1990 4,795,643 1/1989 Seth ........... .. 424/456 4,828,836 5/1989 Elger etal 424/499 _ _ 4,834,985 5/1989 Elger et a1 . 424/469 Relmd 115- APPlIcatwn Data 4,933,105 6/1990 Fong ......... .. 424/497 [63] Continuation of Ser. No. 323,515’ Man 14, 19897 abam 4,996,058 2/1991 Sinnreich .................. .. 424/462 cloned, which is a continuation of Ser. No. 826,172, Feb. 5’ 1986’ abandon“ FOREIGN PATENT DOCUMENTS [51] 111:. C15 ....................... .. A61K 9/26; A61KA61K 31/489/52; 1202885 8/1970 ?génl‘jli'nfi?fmanyUnited Kingdom ""'_j 514/250 [52] US. C1. .................................. .. 424/469; 424/468; 2043671 12/1930 United Kingdom _, 514/250 424/470; 514/249; 514/250 2063670 6/1981 United Kingdom .............
    [Show full text]
  • Platelets by [3H]Dihydroergocryptine Binding
    Identification of a-Adrenergic Receptors in Human Platelets by [3H]Dihydroergocryptine Binding KURT D. NEWMAN, LEWIS T. WILLIAMS, N. HAHR BISHOPRIC, and ROBERT J. LEFKOWITZ, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27710 A B ST RA CT Binding of [3H]dihydroergocryptine to INTRODUCTION platelet lysates appears to have all the characteristics of binding to a-adrenergic receptors. At 25°C binding The endogenous catecholamines epinephrine and nor- reaches equilibrium within 20 min and is reversible epinephrine exert a variety of regulatory functions on upon addition of excess phentolamine. Binding is satu- human physiological processes. The initial sites of ac- rable with 183+22 fmol of [3H]dihydroergocryptine tion of catecholamines seem to be at membrane adren- bound per mg of protein at saturation, corresponding ergic receptors. Based on the relative order of potencies to 220+26 sites per platelet. Kinetic and equilibrium of a series of adrenergic agonists, Ahlquist proposed studies indicate the dissociation constant of [3H]dihy- that the effects of catecholamines were mediated by droergocryptine for the receptors is 1-3 nM. The spec- two distinct types of adrenergic receptors, termed a- ificity of the binding sites is typical of an a-adrenergic and ,3-adrenergic receptors (1). /-Adrenergic responses receptor. Catecholamine agonists compete for occu- (isoproterenol> epinephrine> norepinephrine) which pancy of the [3H]dihydroergocryptine binding sites are specifically antagonized by propranolol are typified with an order of potency (-)epinephrine> (-)norepi- by relaxation of smooth muscle and stimulation of car- nephrine> (-)isoproterenol. Stereospecificity was dem- diac contractility. a-Adrenergic responses (epineph- onstrated inasmuch as the (+)isomers of epinephrine rine> norepinephrine> isoproterenol) are potently an- and norepinephrine were 10-20-fold less potent than tagonized by phentolamine and are typified by con- the (-)isomers.
    [Show full text]
  • Ergoline Alkaloids
    Ergoline Alkaloids Prof. Dr. Ali H. Meriçli GENERALITIES All of the alkaloids in this group are derived from a tetracyclic, octahydroindoloquinoline nucleus, namely ergoline. Although these are commonly classified as clavines, simple lysergic acid derivatives, and ergopeptines, it is also possible, and less ambigous, to classify the various known alkaloids as a function of their basic nucleus. Ergoline nucleus Thus the following are distinguished : 1. Ergoline Alkaloids : Ergoline alkaloids can be substituted at C-8, most often by a methyl group (festuclavine), or a hydroxymethyl group (dihydrolysergol), or at C-8 and C-9 in rare cases. 2. 8-Ergolene Alkaloids . 8-Ergolene Alkaloids can be substituted at C-8 by a methyl group (agroclavine), a hydroxymethyl group (elymoclavine, or a carboxyl group (paspalic acid) 3. 9-Ergolene Alkaloids. 9-Ergolene alkaloids include the chief alkaloids of the ergot of rye, whether they have an amino acid structure (ergometrine), a peptide structure with a cyclol moiety (ergopeptines), or a peptide structure without a cyclol moiety (ergopeptams) 4. Secoergoline Alkaloids. Secoergoline alkaloids have an open D ring (chanoclavine I). 5. Related Structures. Related structures sometimes referred to as proergolines, include the precursor of all these compounds, in other words dimethylallyltryptophan, and products such as clavitipic acids. These alkaloids were initially characterized in the ergot of rye, Claviceps purpurea. Biosynthetic origin Labelling experiments show that the precursor of the ergoline nucleus are tryptophan, mevalonic acid and methionine. Several mechanisms have been proposed to rationalize the first step in the elaboration of ergoline, in other words the formation of dimethylallyltryptophan (= DMAT) : it involves the alkylation of tryptophan by dimethylallyl pyrophosphate, directly at C-4, catalyzed by a specific enzyme, DMAT synthetase.
    [Show full text]